1 Day
Source:
USA TODAY
New drug greatly extends pancreatic cancer survival
A new experimental drug, daraxonrasib, has shown promising results in treating metastatic pancreatic cancer by nearly doubling patient survival in a phase 3 clinical trial. Patients who received the drug lived a median of 13.2 months compared to 6.7 months for those on chemotherapy. The drug targets RAS gene mutations, which are linked to uncontrolled cell growth, and has received early access approval from the FDA, with potential formal approval anticipated later in 2026.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)